After four injections of a therapy called Anktiva, his latest scan came back normal.
The treatment has been studied for more than a decade and has shown promise across multiple cancer types, yet it’s only approved for a narrow form of bladder cancer.
Should potentially life-saving treatments move through the approval process faster for patients with no other options?
The slow march of time is inexorable and irreversible, but that doesn’t mean its effects on our bodies have to be etched in stone.
One of the more intriguing ideas in aging research is that growing old isn’t just a matter of damage accumulating over the years.
It may also be a story of lost information – the gradual breakdown of the molecular instructions that tell cells which genes to use and which to keep quiet.
The MSF/Doctor without Borders event will take place over the weekend of the 8th and 9th September.
The show starts at 4.00pm (UK time) on 8 September. For you local start times click this link: http://www.timeanddate.com/worldclock… will be streamed here: http://www.blogtv.com/People/dprjones SCHEDULE You can find a provisional schedule here: https://spreadsheets.google.com/sprea… You can keep up with updates by following the “Announcement” page on: http://www.magicsandwichshow.com/ DONATION PAGES A link to the Firstgiving donation page is: http://www.firstgiving.com/fundraiser… The justgiving page is here: http://www.justgiving.com/DPR-Jones0 You can also use the ChipIn link on the website. EBAY ITEMS If you have anything that you can donate for auction please send an email to [email protected] Follow us on Twitter / glimpsescience Like us on Facebook
/ brainstormnews Biotechnology News http://tinyurl.com/8nnrnd4 Genetics News http://tinyurl.com/d4u57xe Nanotechnology http://tinyurl.com/ctyoeav Hosted by
/ crowbarazar Contributors
/ thecosmicweb
/ soundofscilence
/ julian.poultonking
/ adrian.ng.3591
/ sogtfo.
It will be streamed here: http://www.blogtv.com/People/dprjones.
SCHEDULE You can find a provisional schedule here: https://spreadsheets.google.com/sprea…
You can keep up with updates by following the \.
Michael Levin’s novel biology demonstrates how material bodies access non-physical patterns. What if we examined these patterns from their own perspective: do they actively seek to ingress into the physical world? Furthermore, how does this framework relate to the concept of angels in religious traditions?
Find the full podcast: • The Hidden Realm of Patterns Animating Lif…
My first conversation with Michael Levin: • Memory Engrams, DNA, Evolution, Platonic R…
Podcast playlist with scientists from Michael Levin’s lab: • Michael Levin+.
From that insight, Dirac built an entirely new formulation of the theory using what he called “q-numbers” (quantum numbers)—abstract quantities that don’t commute. He independently rediscovered aspects of Hilbert’s operator theory, though he preferred his own algebraic route because he found mathematicians’ obsession with convergence and existence theorems unappealing.
Paul Adrien Maurice Dirac (, dih-RAK ; [ 3 ] 8 August 1902 – 20 October 1984) was a British theoretical physicist who is considered to be one of the founders of quantum mechanics. [ 4 ] [ 5 ] Dirac laid the foundations for both quantum electrodynamics and quantum field theory, coining the former term. [ 6 ] [ 7 ] [ 8 ] [ 9 ] He was Lucasian Professor of Mathematics at the University of Cambridge from 1932 to 1969, and a professor of physics at Florida State University from 1970 to 1984. Dirac shared the 1933 Nobel Prize in Physics with Erwin Schrödinger “for the discovery of new productive forms of atomic theory.” [ 10 ]
Dirac graduated from the University of Bristol with a Bachelor of Science in Electrical Engineering in 1921, and a Bachelor of Arts in Mathematics in 1923. [ 11 ] Dirac then graduated from St John’s College, Cambridge, with a Doctor of Philosophy in Physics in 1926, writing the first ever thesis on quantum mechanics. [ 12 ]
He formulated the Dirac equation, one of the most important results in physics, in 1928. [ 7 ] It connected special relativity and quantum mechanics and predicted the existence of antimatter. [ 13 ] He wrote a famous paper in 1931, [ 14 ] which further predicted the existence of antimatter. [ 15 ] [ 16 ] [ 13 ] Dirac also contributed greatly to the reconciliation of general relativity with quantum mechanics. He contributed to Fermi–Dirac statistics, which describes the behaviour of fermions, particles with half-integer spin. His 1930 monograph, The Principles of Quantum Mechanics, is one of the most influential texts on the subject. [ 17 ] He and Schrödinger tied for eighth in a Physics World poll of the greatest physicists of all time. [ 18 ] .
Prolonged manufacturing times for autologous CAR T cell therapies can be incompatible with rapidly progressive disease (PD), resulting in increased need for bridging therapy to achieve disease stabilization. Bridging therapy was required for most patients receiving cilta-cel and ide-cel in clinical trials (75 and 87%, respectively) (7, 9, 11, 12). Although use of bridging therapy may not affect ORR, CRR, or PFS, it is associated with worse overall survival (15). Similarly, as wait times for CAR T cell product increase, so does risk of mortality as effectiveness of the therapy decreases (16, 17), highlighting the need for improved CAR T cell products with faster and more reliable manufacturing.
Another issue associated with traditionally manufactured CAR T cell products is T cell exhaustion due to extended periods of in vitro stimulation and expansion during manufacturing (18). Higher levels of exhausted T cells were also observed in the leukapheresis material and final products from patients who later experienced PD (18). T cell exhaustion can result in poor persistence of CAR T cells in the body, thereby impeding function as the proliferation and survival of transferred T cells strongly correlate with their antitumor activity (19–22). Specific T cell populations have varying abilities to expand and persist in vivo. Memory (CD8+CD45RO−CD27+) and naive T cell (TN cell) subsets are associated with improved clinical response, given their ability to proliferate and persist after infusion, whereas effector T cell subsets comparatively exhibit lower self-renewal and survival capabilities (19, 23, 24). Although these patient-specific parameters are initially established in leukapheresis material, preservation of such cell populations in the final product via manufacturing techniques may improve the antitumor activity of a patient’s CAR T cell therapy (18, 19, 23, 24).
Durcabtagene autoleucel (PHE885) is an autologous, BCMA-targeting CAR T cell therapy carrying a CAR construct with a fully human anti-BCMA single-chain fragment variable (scFv) fused to 4-1BB/CD3ζ signaling domains manufactured on a next-generation platform. Prior work has shown that this platform can successfully manufacture product in fewer than 2 days by eliminating the need for ex vivo expansion, thereby preserving overall T cell stemness (the ability of T cells to self-renew and mature), which results in a final product with greater proliferative potential and fewer exhausted T cells (18). Here, we present the findings of part A of the phase 1 study (NCT04318327) of durcabtagene autoleucel in r/r MM, along with correlative analyses of the product before and after infusion.
